将基因组学整合入肝细胞癌临床实践:面临的挑战
本文综述肝细胞癌基因组学认识现状及将分子谱分析转化为临床实践的局限,并评估已获批晚期肝细胞癌全身治疗的有效性与获益。
要点
- 美国肝细胞癌发病率和死亡率持续上升,多数患者确诊时已属晚期。
- 全基因组表达谱分析已鉴定肝细胞癌突变谱,但最高频突变不适于药物开发。
- 近十年来多个一线和二线全身化疗药物首次获批用于肝细胞癌。
核心结论
- 尽管分子谱分析取得进展,最高频突变不适于药物开发,晚期肝细胞癌的治愈性治疗仍难以实现。
研究设计与样本
- 综述,聚焦肝细胞癌基因组学当前认识及分子谱分析转化为临床实践的局限,并评估已获批晚期肝细胞癌全身治疗的有效性与获益。
主要发现
- 美国肝细胞癌发病率和死亡率持续上升,多数患者就诊时已属晚期,治愈性治疗和长期生存可能性低。
- 全基因组表达谱分析进展已鉴定肝细胞癌突变谱。
- 近十年来多个一线和二线全身化疗药物首次获批用于肝细胞癌。
- 最高频突变不适于药物开发,晚期肝细胞癌治愈性治疗仍难以实现。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The incidence and mortality related to hepatocellular carcinoma (HCC) continue to increase in the United States, with most patients presenting at advanced stages where curative therapy and long-term survival is unlikely. Fortunately, significant progress has been made in identifying the landscape of HCC mutations due to advances in whole genome expression profiling. Drug development has also evolved in recent years with multiple first- and second-line systemic chemotherapy agents approved for HCC for the first time in over a decade. However, despite advances in molecular profiling, mutations that were identified at the highest frequency were not amenable to drug development, and curative therapy for advanced HCC remains elusive. This review focuses on the current understanding of HCC genomics and the limitations of translating the current HCC molecular profiling into clinical practice and examines the effectiveness and benefits of approved systemic therapies for advanced HCC.
引用
- Pillai A, Ahn J, Kulik L, et al. Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead. Am J Gastroenterol. 2020. PMID: 33038134. doi:10.14309/ajg.0000000000000843
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。